Search
Search Results
##search.searchResults.foundPlural##
-
A CRITICAL HISTORY OF CHRONIC MYELOID LEUKEMIA
3242PDF: 1336HTML: 4131 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1730PDF: 1166HTML: 246 -
ANTIFUNGAL PROPHYLAXIS IN IMMUNOCOMPROMISED PATIENTS
4316PDF: 1374HTML: 2041 -
A rare case of multidrug resistant Leclercia adecarboxylata catheter-related bloodstream infection and an updated brief literature review Leclercia adecarboxylata catheter-related bloodstream infection.
832PDF: 557HTML: 162 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2094PDF: 1528HTML: 286 -
IMMUNOLOGICAL EVOLUTION OF A COHORT OF HIV-2 INFECTED PATIENTS: PECULIARITIES OF AN UNDERESTIMATED INFECTION HIV-2 INFECTED PATIENTS PECULIARITIES
977PDF: 618HTML: 227 -
GROUP-BASED TRAJECTORY MODELING OF PLATELET IN PATIENTS WITH APLASTIC ANEMIA: A STUDY BASED ON THE MIMIC DATABASE
1006PDF: 996Suppl. Files: 636HTML: 139 -
THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies
1538PDF: 542HTML: 273 -
CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
4812PDF: 1788HTML: 2707Untitled: 220 -
GILTERITINIB (XOSPATA ®) IN TURKEY: EARLY ACCESS PROGRAM RESULTS Gilteritinib (XOSPATA ®) in Turkey
1432PDF: 905Suppl. Files: 456HTML: 237 -
CLINICAL ASPECTS OF UNCOMPLICATED AND SEVERE MALARIA
7975PDF: 4147HTML: 7371 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1619PDF: 810HTML: 166 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2224PDF: 1048HTML: 1984Characteristic of study group: 199 -
Acute Panmyelosis with Myelofibrosis - A Rare Subtype of Acute Myeloid Leukemia
2844PDF: 972HTML: 3130flowcytometric result of peripheral blood sample: 180 -
QUALITY OF LIFE ASSESSMENT IN MULTIPLE MYELOMA PATIENTS UNDERGOING DOSE-REDUCED TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION
1394PDF: 681HTML: 1378cover letter: 206 -
CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.
4256PDF: 1518HTML: 448 -
INTEREST IN DETERMINING THE CD34+ CD38- PHENOTYPE IN THE DIAGNOSIS AND PROGNOSIS OF ACUTE LEUKEMIA IN ABIDJAN – CÔTE D’IVOIRE
1964PDF: 713HTML: 684Table1: patient's characteristics: 156Table 2: profile of each patient: 178 -
-
NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?
3259PDF: 1709HTML: 1086 -
PATHOGENESIS AND TREATMENT OF THROMBOHEMORRHAGIC DIATHESIS IN ACUTE PROMYELOCYTIC LEUKEMIA
1811PDF: 809HTML: 10235Figures 1,2,3: 175 -
Successful treatment with eltrombopag in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia
1369PDF: 819HTML: 1026Untitled: 186 -
LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
1626PDF: 799HTML: 862jdoe, table 2 infections CML .doc: 194jdoe, table 1 infections CML .doc: 181 -
IMPACT OF QUALITATIVE AND QUANTITATIVE IMMUNOPARESIS ON EARLY INFECTION RISK IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA Immunoparesis and early infection risk in myeloma
0PDF: 0HTML: 0







